Menu
← Oncology Approval Tracker
FDA DECISION ·
Augtyro
repotrectinib · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with ROS1-positive non-small cell lung cancer that is locally advanced or metastatic.
LAMPGEN ANALYSIS
Why it matters
A ROS1 inhibitor expanded the targeted treatment options for this molecular subtype.
What research teams should watch
Document the ROS1 result and prior targeted therapy to interpret cohort-specific evidence.
PRIMARY RECORDS